Track topics on Twitter Track topics that are important to you
DelveInsight's Graft versus Host Disease GVHD Market Insights, Epidemiology and Market Forecast2023Japan report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed incident cases of Hematopoietic stem cell transplantations HSCTs and Graft Versus Host Disease GVHD based upon the subtypes of GVHD along with the type of donor involved in the HSCTs, for the forecast period 20132023. The report also includes global market size of the Graft Versus Host Disease GVHD for Japan.
GVHD is one of the severe complications associated with Hematopoietic stem cell transplantations HSCTs. DelveInsight forecasts predict an ongoing increase in HSCTs in the near future which shall lead to subsequent increase in the patient population of GVHD. According to DelveInsight's estimates, the total number of diagnosed incident cases of Hematopoietic Stem Cell Transplants HSCTs shall increase at a Compound Annual Growth Rate CAGR of 2.73% from 20132023 and reach up to 7,025 cases in the year 2023.
The incident rate of GVHD in unrelated donor URD is much higher in comparison to the sibling donors SD, irrespective of the subtypes i.e., acute GVHD aGVHD or chronic GVHD cGVHD. As per DelveInsight forecasts, the diagnosed incidence cases of aGVHD in sibling donors and aGVHD in unrelated donors, shall increase at a CAGR of 2.88 % and 1.57%, respectively, from 20132023. In case of cGVHD, the number of diagnosed incident population cGVHD in sibling donors and cGVHD in unrelated donors is expected to accentuate at a CAGR of 2.88% and 1.57%, respectively, by the end of the year 2023.
The market size of GVHD mainly comprises of the offlabel biologics. Many companies are working on the development of targeted therapy and in the near future, these drugs may create an impact on the overall market size of GVHD. DelveInsight's estimates suggest that the forecasted market size of Graft Versus Host Disease GVHD in Japan shall increase at a CAGR of 4.80% from 2013 to 2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse Forecast model analysis by Publisher team of industry experts.
Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
It focuses on the risk factors and the historical trends of the diagnosed incident cases of allogeneic Hematopoietic Stem Cell Transplants HSCTs which also includes the cases of first transplants along with the total transplants
The Report also covers the detailed historical and forecasted number of diagnosed incident cases of acute GVHD and chronic GVHD, segmented by the type of donors Sibling donors and unrelated donors for Japan from 20132023.
The Report also includes historical and forecasted Market size of GVHD for Japan from 2013 to 2023.
It provides the information of available marketed therapies, including offlabel biologics, patent and exclusivity details.
The report also focuses on the details of pipeline drugs in the pivotal stage of development including their SWOT Analysis and expected launch date, which shall help to predict the impact of those drugs on the market size in the near future.
Track and monitor developments in stem cell research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry. BioPort...
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...